KNBI.F Stock Overview
A biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kane Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.077 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.062 |
| Beta | 0.51 |
| 1 Month Change | 0.65% |
| 3 Month Change | 1.28% |
| 1 Year Change | 17.07% |
| 3 Year Change | -22.50% |
| 5 Year Change | -43.43% |
| Change since IPO | -86.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNBI.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.8% | 1.3% | 0.2% |
| 1Y | 17.1% | 0.9% | 22.0% |
Return vs Industry: KNBI.F exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: KNBI.F underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| KNBI.F volatility | |
|---|---|
| KNBI.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNBI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KNBI.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Marc Edwards | kanebiotech.com |
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Kane Biotech Inc. Fundamentals Summary
| KNBI.F fundamental statistics | |
|---|---|
| Market cap | US$11.57m |
| Earnings (TTM) | -US$3.43m |
| Revenue (TTM) | US$1.41m |
8.2x
P/S Ratio-3.4x
P/E RatioIs KNBI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNBI.F income statement (TTM) | |
|---|---|
| Revenue | CA$2.01m |
| Cost of Revenue | CA$1.02m |
| Gross Profit | CA$993.60k |
| Other Expenses | CA$5.90m |
| Earnings | -CA$4.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 49.36% |
| Net Profit Margin | -243.98% |
| Debt/Equity Ratio | -201.8% |
How did KNBI.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 10:41 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.